Trial Profile
Randomized Phase II Trial Assessing the Combination of Nexavar (Sorafenib), and Gemcitabine/Oxaliplatin in Patients Treated for Advanced (Unresectable/Metastatic) Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- Acronyms PRODIGE 10
- 04 Apr 2019 Results published in the British Journal of Cancer
- 31 May 2013 Primary endpoint 'Progression-free-survival-rate' has been met.
- 31 May 2013 Final results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.